NCT03664843

Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

A Prospective Multicenter Study of Longitudinal Monitoring in Treated Stage III-IV Lung Cancer Patients by Circulating Tumor DNA

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: First Hospital of Shijiazhuang City · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.

Detailed description

The study consists of two phases, the first stage is the exploratory stage of blood collection point which is the appropriate effective time after chemotherapy, radiotherapy, targeted therapy. The second phase, which is the expansion of the first phase, is to determine the precise leading time of ctDNA relative to tumor biomarkers or image evaluation in determining the efficacy of advanced NSCLC cancer therapy. Both stages were divided into three subgroups: the chemotherapy group, the radiotherapy group, and the targeted therapy group.

Conditions

• Carcinoma
• Non-small Cell Lung Cancer
• Lung Neoplasm

Timeline

• Start date: 2018-11-09
• Primary completion: 2020-05-01
• Completion: 2020-09-01
• First posted: 2018-09-11
• Last updated: 2018-11-13

Locations

8 sites across 1 country: China